Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Vanguard High Dividend Yield ETFTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Vanguard High Dividend Yield ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.69 (market cap $29.60B), while Vanguard High Dividend Yield ETF trades at $166.82. The key difference: Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYVYM
Market Cap
$29.60B
Sector
Health
52-Week High
$491.22$166.14
52-Week Low
$205.48$136.63
Enterprise Value
$27.56B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.

The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.

Vanguard High Dividend Yield ETF

VYM trades at $166.51, up 0.27% with a bullish technical signal from moving averages but overbought RSI readings. The ETF recently hit a new 52-week high and maintains strong institutional interest despite some position reductions. Recent news highlights VYM's role in retirement income strategies with a 2.2% dividend yield and decade-long performance comparisons to the S&P 500.

The outlook remains positive for income-focused investors given VYM's sustainable dividend growth and sector diversification. Key risks include potential underperformance versus growth indices and sensitivity to interest rate changes. Wall Street sentiment is generally favorable with the ETF positioned as a core holding for retirement portfolios.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Vanguard High Dividend Yield ETF

The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VYM